Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index.
about
Fabry disease: recent advances in pathology, diagnosis, treatment and monitoringAgalsidase alfa: a review of its use in the management of Fabry diseaseNervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapyFunctional studies of new GLA gene mutations leading to conformational Fabry disease.Update on role of agalsidase alfa in management of Fabry disease.Ocular signs correlate well with disease severity and genotype in Fabry disease.Gene therapy for lysosomal storage diseases (LSDs) in large animal models.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Gastrointestinal Symptoms of Patients with Fabry Disease.Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Genetic variants associated with gastrointestinal symptoms in Fabry disease.Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Fabry disease
P2860
Q21202889-7D26D556-4AC5-4F74-9FDC-F1211927BAD6Q28274194-893F4239-9E54-450E-A973-2BA4D8453C31Q33847189-9AA8940E-9F07-4F68-A970-E6C9A89A0038Q34665552-AF03BE44-5A7B-4D3D-9FD6-ED42BD7CA365Q34883178-7CFFA8A1-1E8A-4B55-B093-62DB84B0890FQ35187827-7ACA6E4F-B3AC-4618-BFB2-7F3CBCEEF21AQ35923476-BD9DFBFC-BF7F-401D-A3DF-ACC57799A872Q36309032-5B810CDF-DDAF-4607-8C9D-9C1EFF4E5E87Q36529707-C84FD3F9-2057-4683-A74E-52B47A320C39Q37029946-7F248DA7-B78F-4A12-A367-5979C0653D2BQ37775790-37A527A7-107D-4741-8808-58025A234CA5Q37801828-3A5A7F26-1EE9-4F92-B10B-62CFDC33B2C4Q42316513-FB27B2C0-1B7B-461B-9C2C-B06AC2AFA34BQ47094778-F74AE2E5-C99B-4823-872F-FDBB6B8267BEQ56905945-BC6C31C5-054B-4727-B054-8DDA27AB29ED
P2860
Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@en
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@nl
type
label
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@en
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@nl
prefLabel
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@en
Enzyme replacement therapy wit ...... he Mainz Severity Score Index.
@nl
P2093
P1433
P1476
Enzyme replacement therapy wit ...... the Mainz Severity Score Index
@en
P2093
D Concolino
G Valsecchi
P De Lorenzo
P Strisciuglio
R Ravaglia
P304
P356
10.1111/J.1399-0004.2008.01012.X
P577
2008-04-24T00:00:00Z